These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5158658)

  • 1. [Immunogenic properties of an experimental vaccine against foot-and-mouth disease].
    Siusiukin AA; Kravets IK; Tsvetkova NE; Pavlov VG
    Veterinariia; 1971 May; 5():40-2. PubMed ID: 5158658
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen.
    Sen AK; Saha SN
    Acta Virol; 1994 Feb; 38(1):17-9. PubMed ID: 8067308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenic properties of inactivated cultured foot-and-mouth disease vaccine].
    Siusiukin AA; Kravets IK; Siusiukina MS; Efimov NI; Sergeev VA; Mel'nik RI
    Veterinariia; 1967 Apr; 44(4):17-8. PubMed ID: 5615318
    [No Abstract]   [Full Text] [Related]  

  • 4. Early response of cattle and swine to inactivated foot-and-mouth disease vaccine.
    Graves JH; McKercher PD; Farris HE; Cowan KM
    Res Vet Sci; 1968 Jan; 9(1):35-40. PubMed ID: 5689040
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative testing of methods for the control of foot-and-mouth disease vaccines on guinea pigs].
    Tekerlekov P; Mitev G; Nikolova E; Gergov P
    Vet Med Nauki; 1975; 12(1):25-9. PubMed ID: 1209994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [On the immunizing properties of GOAL-formol vaccine and GNKI dry virus vaccine against foot-and-mouth disease].
    Lazarev PS; Amelin IP; Zaslonov MS
    Veterinariia; 1966 Sep; 43(9):30-1. PubMed ID: 6011469
    [No Abstract]   [Full Text] [Related]  

  • 8. [The efficacy of foot and mouth disease vaccines after long- term storage].
    Wittmann G
    Berl Munch Tierarztl Wochenschr; 1980 Jan; 93(2):33-4. PubMed ID: 6248022
    [No Abstract]   [Full Text] [Related]  

  • 9. [On the production of monovalent foot-and-mouth disease vaccine concentrate from tissue culture virus type O].
    Mitev G; Wassilewa L; Tekerlekov P
    Arch Exp Veterinarmed; 1966 Mar; 20(1):85-90. PubMed ID: 4293436
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes.
    Li G; Chen W; Yan W; Zhao K; Liu M; Zhang J; Fei L; Xu Q; Sheng Z; Lu Y; Zheng Z
    Virology; 2004 Oct; 328(2):274-81. PubMed ID: 15464847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary study of the synergy of variants in the matter of foot-and-mouth disease. Action on the immunogenic quality of antiaphthous vaccines].
    Fontaine J; Roumiantzeff M; Dubouclard C; Mackowiak C
    Bull Acad Vet Fr; 1966 Jun; 39(6):229-37. PubMed ID: 6006997
    [No Abstract]   [Full Text] [Related]  

  • 12. Experiments on an early protection against foot-and-mouth disease virus.
    Liebermann HT; Thalmann G; Bartels T; Nöckler A
    Acta Virol; 1993; 37(2-3):181-3. PubMed ID: 8105663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of an emergency vaccine against foot and mouth disease in pigs].
    Eblé P
    Tijdschr Diergeneeskd; 2007 Aug; 132(16):617-9. PubMed ID: 17849910
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
    Yao Q; Qian P; Huang Q; Cao Y; Chen H
    J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apropos of the conclusions (Point I, Section E) of the 11th conference of the Permanent Commission on Foot-and-Mouth Disease of the International Office of Epizootic Diseases in Paris].
    Röhrer H
    Bull Off Int Epizoot; 1966; 65(11):1921-8. PubMed ID: 5994040
    [No Abstract]   [Full Text] [Related]  

  • 16. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant P1 polyprotein expressed in Pichia pastoris.
    Balamurugan V; Renji R; Venkatesh G; Reddy GR; Nair SP; Ganesh K; Suryanarayana VV
    Arch Virol; 2005 May; 150(5):967-79. PubMed ID: 15662485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specific immunoprophylaxis trials with calves against foot-and-mouth disease].
    Tekerlekov P; Uruchev K; Nikolova E; Genov I; Tsutsumanski V
    Vet Med Nauki; 1980; 17(2):28-35. PubMed ID: 6254238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle.
    Fowler VL; Paton DJ; Rieder E; Barnett PV
    Vaccine; 2008 Apr; 26(16):1982-9. PubMed ID: 18342409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE; Kumar N; Thulke HH; Haas B
    Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines.
    Hyslop NS; Morrow AW
    Res Vet Sci; 1969 Mar; 10(2):109-20. PubMed ID: 5818030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.